CC — Stock Film
STOCK FILMSCENE 1/11CC · $17.18
Stock Expert AI presents
CC
The Chemours Company
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
The Chemours Company. A quick introduction.

On the stock market since 2015, it operates in the world of raw materials. It has 5,700 employees. Now — the numbers.

on the stock market since 2015
5,700 employees
$2.6B market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.1.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

WHERE DOES THE MONEY COME FROM?
42%Titanium Technologies
Titanium Technologies 42%Thermal and Specialized Solutions 36%Advanced Performance Materials 22%
42% of all revenue comes from a single line: Titanium Technologies.

Revenue is spread across several lines; no single product carries the company.

In the vault right now:
$0
DEBT: $4.6B
At this pace, that money lasts about 1.7 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
25
very weak

Clearly below the class average.

FINANCIAL STRENGTH
4
very weak

Clearly below the class average.

VALUATION
55
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
28
very weak

Clearly below the class average.

PRICE MOMENTUM
40
weak

Clearly below the class average.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Business Quality: Profit power and business quality trail similar companies in the sector.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Few are betting against it10/10
WEAK SPOTS
Little set aside for the future2/10
Thin profit on each sale3/10
Growth has stalled4/10
WORTH WATCHING

R&D Investment: Spending on future research is low.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 62% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
Sales are holding up

The company sells $5.8B a year; the problem isn’t sales — it’s costs running above that number.

2
THE BRIGHT SIDE · 2/3
Executives are buying their own stock

Over the last 12 months, company executives reported 27 buys and 15 sells. Management buying with its own money is usually read as a good sign.

3
THE BRIGHT SIDE · 3/3
Analysts’ target sits above today’s price

The average analyst price target is $25.7550% above today’s price.

1
THE RISKS · 1/2
Lost money last year

A loss of $386M against $5.8B in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts about 1.7 years. After that, the company needs to find new money.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, CC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: CC has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

Analysts’ average target sits above today’s price, yet the valuation grade (55/100) says the stock isn’t cheap.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film